EZH2 and ovarian serous adenocarcinoma: A recent report using 17 primary serous ovarian cancer patients and in vitro models showed that EZH2 loss drives resistance to carboplatin and paclitaxel in serous ovarian cancers that express Ataxia Telangiectasia Mutated (ATM) [148].